Levemir Related Published Studies
Well-designed clinical trials related to Levemir (Insulin Detemir Subcutaneous)
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. [2008.08.27]
Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. [2008.08]
Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. [2008.08]
Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. [2008.07.17]
Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. [2008.04]
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. [2008.03]
Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. [2008.03]
Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. [2008.01]
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. [2007.10.25]
Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. [2007.10]
Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. [2007.06]
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. [2007.05]
Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. [2007.01]
Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. [2007]
Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. [2007]
Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. [2006.09]
Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. [2006.07]
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. [2006.06]
Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. [2005.07]
A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. [2005.05]
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. [2005.01]
Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. [2005.01]
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. [2004.11]
The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. [2004.10]
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. [2004.06]
Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. [2004.05]
Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. [2004.05]
Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. [2004.04]
Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. [2003.11]
Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. [2003.03]
Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. [2001.02]
Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. [2000]
Other research related to Levemir (Insulin Detemir Subcutaneous)
A comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: the ADAPTTM Study. [2008.10.22]
Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. [2008.10]
Safety, simplicity and convenience of a modified prefilled insulin pen. [2008.09]
Evaluation of the injection force dynamics of a modified prefilled insulin pen. [2008.09]
Indirect Comparison of Once Daily Insulin Detemir and Glargine in Reducing Weight Gain and Hypoglycaemic Episodes when Administered in Addition to Conventional Oral Anti-Diabetic Therapy in Patients with Type-2 Diabetes. [2008.08.01]
An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update). [2008.08]
Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. [2008.06]
[Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark] [2008.04.07]
Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. [2008.04]
A case of lipoatrophy with insulin detemir. [2008.04]
Role of insulin signaling in maintaining energy homeostasis. [2008.04]
Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. [2008.02]
Insulin analogues: action profiles beyond glycaemic control. [2008.02]
Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. [2008.01]
[Long-term improvement of fasting glycaemia after switching basal insulin from NPH to determir in children with type 1 diabetes: a 1-year multicentre study] [2008]
Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. [2008]
Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. [2008]
Prevailing therapeutic regimes and predictive factors for prandial insulin substitution in 26 687 children and adolescents with Type 1 diabetes in Germany and Austria. [2007.12]
Cerebrocortical beta activity in overweight humans responds to insulin detemir. [2007.11.21]
The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes - results of the randomized, controlled PREDICTIVEtrade mark 303 study. [2007.11]
Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. [2007.11]
Insulin-associated weight gain in diabetes--causes, effects and coping strategies. [2007.11]
Which basal insulin should be used in patients with type 2 diabetes mellitus? [2007.10]
Optimizing insulin use in type 2 diabetes: role of basal and prandial insulin in long-term care facilities. [2007.10]
Insulin detemir: a new option for the treatment of diabetes. [2007.10]
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. [2007.09.21]
Refining basal insulin therapy: what have we learned in the age of analogues? [2007.09]
Insulin glulisine: a faster onset of action compared with insulin lispro. [2007.09]
Patient perceptions of insulin detemir as reported through patient telephone surveys. [2007.09]
Efficacy and safety of insulin detemir. [2007.08]
Levemir Early Clinical Experience Case Series. [2007.08]
Intensive diabetes therapy and body weight: focus on insulin detemir. [2007.08]
Pharmacology of insulin detemir. [2007.08]
Insulin detemir and basal insulin therapy. [2007.08]
Proportional Dose-Response Relationship and Lower Within-Patient Variability of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes Mellitus. [2007.07]
A review of human and analogue insulin trials. [2007.07]
Actions of insulin beyond glycemic control: a perspective on insulin detemir. [2007.07]
Insulin analogues in the treatment of diabetes in pregnancy. [2007.06]
Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs. [2007.05.17]
PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. [2007.05]
Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. [2007.05]
Does insulin detemir have a role in reducing risk of insulin-associated weight gain? [2007.05]
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. [2007.04.18]
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. [2007.04]
Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. [2007.03]
Update in the pharmacologic treatment of diabetes: focus on insulin detemir, insulin glulisine, and inhaled dry powdered insulin. [2007.03]
Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. [2007.03]
Insulin analogues: new dimension of management of diabetes mellitus. [2007.01]
Defining the role of insulin detemir in Basal insulin therapy. [2007]
Insulin detemir: A long-acting insulin product. [2006.12.15]
Insulin detemir: a review. [2006.08]
Insulin detemir in the treatment of type 1 and type 2 diabetes. [2006]
[An update on multiple insulin injection therapy in type 1 and 2 diabetes] [2006]
Other possibly related research studies
New therapeutic options for the management of diabetes. [2007.01]
New drugs 07, part I. [2007.02]
[Results of the PREDICTIVE project in the Czech Republic] [2008.04]
Gateways to clinical trials. [2007.11]
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. [2007]
Gateways to clinical trials. [2008.03]
|
